Announcing MAP’s conference 2020
Patient Access 2020: Innovation for UK market access
Tuesday 22nd September 2020 – Royal College of Physicians, London
A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.
Our conference has been designed around three core market access areas. Each with a specific mission to bring you the latest insights and information for accelerating patient access.
Developments in strategy and HTA
The importance of patient engagement throughout the HTA process
Using patient registries in HTAs
Appraisal process of medical devices compared with drugs
Health economic modelling of digital apps
Access to Orphan Medicines: Developing policies for the future
Innovation tools
Approaches to utilising Real World Evidence (RWE)
Using analytics and big data to gain competitive advantage in Market Access
Collaborative working and horizon scanning
Harnessing digital systems and technology to find new levels of patient value
Pricing and policy
VPAS – what you need to know
Updates on The Commercial Framework
Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
The NHS Long Term Plan and what this actually means for pharma companies
Confirmed Speakers
- Lindsay Weaver, CEO, Metabolic Support UK – on the importance of patient engagement throughout the HTA process
- David Gillen, Vice President international Medical Affairs, Vertex – on using patient registries in HTAs
- Sheela Uppadhyaya, Associate Director Technology Appraisals and Highly Specialised Technologies, NICE – on Orphan medicines, policy and patient engagement
- Andi Orlowski, Head of Business Intelligence, Imperial College Healthcare Partners – on approaches to utilising Real World Evidence (RWE)
- David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI) – on the Voluntary Scheme; what you need to know
- Darren Spevick, Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group – on Harnessing digital systems and technology to find new levels of patient value
Who should attend?
This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.
The job functions that will benefit most include:
- Heads of Market Access
- Country Managers
- Health Economists
- Commercial Directors
- Marketing Directors
- Managing Directors
- Chief Executives
- Medical Directors
- Policy Officers/Executives
- Policy Advisors
